UBS Group
APGE

UBS Group’s Apogee Therapeutics APGE Stock Holding History

UBS Group’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.8M Sell
201,831
-942,497
-82% -$84.9M ﹤0.01% 2385
2026
Q1 		$96.3M Buy
1,144,328
+169,502
+17% +$12.3M 0.01% 1080
2025
Q4 		$73.6M Buy
974,826
+175,361
+22% +$11M 0.01% 1260
2025
Q3 		$31.8M Buy
799,465
+692,308
+646% +$26.4M 0.01% 2069
2025
Q2 		$4.65M Sell
107,157
-594,752
-85% -$22.6M ﹤0.01% 3965
2025
Q1 		$26.2M Buy
701,909
+160,623
+30% +$6.21M ﹤0.01% 2092
2024
Q4 		$24.5M Buy
541,286
+489,466
+945% +$25M ﹤0.01% 2124
2024
Q3 		$3.04M Buy
51,820
+1,330
+3% +$63.7K ﹤0.01% 3571
2024
Q2 		$1.99M Sell
50,490
-25,541
-34% -$1.24M ﹤0.01% 3773
2024
Q1 		$5.05M Buy
+76,031
New +$3.32M ﹤0.01% 2961
2023
Q4 		– Sell
-3,557
Closed -$75.8K – 9271
2023
Q3 		$75.8K Buy
+3,557
New +$78.4K ﹤0.01% 6025

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

UBS Group's APGE Position: Q2 2026 in Review

UBS Group reduced its Apogee Therapeutics (APGE) stake by 82% in Q2 2026, selling an estimated $84.9M and leaving 201,831 shares worth $26.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2385.

UBS Group first reported a position in APGE in Q3 2023 and has held it in 11 quarters since. The position peaked at $96.3M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • UBS Group held 201,831 shares of Apogee Therapeutics worth $26.8M as of Q2 2026.
  • UBS Group sold 942,497 Apogee Therapeutics shares in Q2 2026, an estimated $84.9M.
  • Apogee Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2385 holding.
  • UBS Group first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • UBS Group's Apogee Therapeutics position peaked at $96.3M in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.